Cencora lifts guidance on specialty drug strength, adds buyback and AI push
Profit outlook raised again on specialty drugs Cencora beat profit estimates and raised its full-year earnings guidance, with adjusted operating income up 17% as specialty and cancer-care businesses grew. Higher expected profits make the shares worth more to investors, which is why the stock rose.
The repeated guidance raise and profit beat are the core force lifting COR.
$1 billion buyback finished early Cencora bought back $1 billion of its own stock in the quarter, finishing a program it had planned to spread through 2026, and kept paying its dividend. Fewer shares outstanding lifts earnings per share and signals confidence, supporting the price.
Buybacks directly shrink share count and support the stock price.
New cell and gene therapy service for hospitals Cencora launched a service helping hospitals set up cell and gene therapy programs, a fast-growing area where most hospital pharmacy leaders say they are unprepared. This opens a new source of demand and fees, supporting future revenue growth.
It is a new business line that expands COR's addressable market.
AI speeds decisions, but costs and thin GLP-1 margins bite Cencora says AI roughly halves the time for some treatment decisions, a plus for its technology story. But GLP-1 drugs carry lower margins, interest costs jumped 72% after the OneOncology deal, and it lost an oncology customer, weighing on results.
It gives the fair counterweight: real positives alongside margin and cost pressures.